Mutational landscape and clonal architecture in grade II and III gliomas
- PMID: 25848751
- DOI: 10.1038/ng.3273
Mutational landscape and clonal architecture in grade II and III gliomas
Abstract
Grade II and III gliomas are generally slowly progressing brain cancers, many of which eventually transform into more aggressive tumors. Despite recent findings of frequent mutations in IDH1 and other genes, knowledge about their pathogenesis is still incomplete. Here, combining two large sets of high-throughput sequencing data, we delineate the entire picture of genetic alterations and affected pathways in these glioma types, with sensitive detection of driver genes. Grade II and III gliomas comprise three distinct subtypes characterized by discrete sets of mutations and distinct clinical behaviors. Mutations showed significant positive and negative correlations and a chronological hierarchy, as inferred from different allelic burdens among coexisting mutations, suggesting that there is functional interplay between the mutations that drive clonal selection. Extensive serial and multi-regional sampling analyses further supported this finding and also identified a high degree of temporal and spatial heterogeneity generated during tumor expansion and relapse, which is likely shaped by the complex but ordered processes of multiple clonal selection and evolutionary events.
Comment in
-
Treatment of WHO Grade 2 and 3 Gliomas With Potentially Favorable Survival: Is Monotherapy Obsolete?Int J Radiat Oncol Biol Phys. 2019 Mar 1;103(3):533-536. doi: 10.1016/j.ijrobp.2018.08.025. Epub 2019 Feb 1. Int J Radiat Oncol Biol Phys. 2019. PMID: 31088778 No abstract available.
Similar articles
-
PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.Acta Neuropathol Commun. 2015 Dec 23;3:88. doi: 10.1186/s40478-015-0265-4. Acta Neuropathol Commun. 2015. PMID: 26699864 Free PMC article.
-
Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas.Acta Neuropathol Commun. 2017 Oct 30;5(1):78. doi: 10.1186/s40478-017-0479-8. Acta Neuropathol Commun. 2017. PMID: 29084603 Free PMC article.
-
DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development.Acta Neuropathol Commun. 2019 Apr 25;7(1):59. doi: 10.1186/s40478-019-0704-8. Acta Neuropathol Commun. 2019. PMID: 31023364 Free PMC article.
-
Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.Curr Treat Options Oncol. 2016 Aug;17(8):42. doi: 10.1007/s11864-016-0418-0. Curr Treat Options Oncol. 2016. PMID: 27334978 Review.
-
TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.Crit Rev Oncol Hematol. 2017 Dec;120:1-9. doi: 10.1016/j.critrevonc.2017.09.013. Epub 2017 Oct 3. Crit Rev Oncol Hematol. 2017. PMID: 29198322 Review.
Cited by
-
Co-expression modules of NF1, PTEN and sprouty enable distinction of adult diffuse gliomas according to pathway activities of receptor tyrosine kinases.Oncotarget. 2016 Sep 13;7(37):59098-59114. doi: 10.18632/oncotarget.10359. Oncotarget. 2016. PMID: 27385209 Free PMC article.
-
Distinguishing IDH mutation status in gliomas using FTIR-ATR spectra of peripheral blood plasma indicating clear traces of protein amyloid aggregation.BMC Cancer. 2024 Feb 16;24(1):222. doi: 10.1186/s12885-024-11970-y. BMC Cancer. 2024. PMID: 38365669 Free PMC article.
-
Systematic identification of mutations and copy number alterations associated with cancer patient prognosis.Elife. 2018 Dec 11;7:e39217. doi: 10.7554/eLife.39217. Elife. 2018. PMID: 30526857 Free PMC article.
-
Molecular landscape of IDH-mutant astrocytoma and oligodendroglioma grade 2 indicate tumor purity as an underlying genomic factor.Mol Med. 2022 Mar 14;28(1):34. doi: 10.1186/s10020-022-00454-z. Mol Med. 2022. PMID: 35287567 Free PMC article.
-
Development and Validation of an IDH1-Associated Immune Prognostic Signature for Diffuse Lower-Grade Glioma.Front Oncol. 2019 Nov 22;9:1310. doi: 10.3389/fonc.2019.01310. eCollection 2019. Front Oncol. 2019. PMID: 31824866 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous